325 related articles for article (PubMed ID: 9688449)
21. A perspective on the present contribution of beta-lactamases to bacterial resistance with particular reference to induction of beta-lactamase and its clinical significance.
Neu HC; Chin NX
Chemioterapia; 1985 Feb; 4(1):63-70. PubMed ID: 3872725
[TBL] [Abstract][Full Text] [Related]
22. Energetic, structural, and antimicrobial analyses of beta-lactam side chain recognition by beta-lactamases.
Caselli E; Powers RA; Blasczcak LC; Wu CY; Prati F; Shoichet BK
Chem Biol; 2001 Jan; 8(1):17-31. PubMed ID: 11182316
[TBL] [Abstract][Full Text] [Related]
23. [Beta-lactamases and their role in resistance. PART 2: beta-lactamases in 21st century].
Bedenić B
Lijec Vjesn; 2005; 127(1-2):12-21. PubMed ID: 16145868
[TBL] [Abstract][Full Text] [Related]
24. Refined crystal structure of beta-lactamase from Citrobacter freundii indicates a mechanism for beta-lactam hydrolysis.
Oefner C; D'Arcy A; Daly JJ; Gubernator K; Charnas RL; Heinze I; Hubschwerlen C; Winkler FK
Nature; 1990 Jan; 343(6255):284-8. PubMed ID: 2300174
[TBL] [Abstract][Full Text] [Related]
25. Determinants of the activity of beta-lactamase inhibitor combinations.
Livermore DM
J Antimicrob Chemother; 1993 Jan; 31 Suppl A():9-21. PubMed ID: 8449836
[TBL] [Abstract][Full Text] [Related]
26. Beta-lactam resistance in anaerobic bacteria: a review.
Hedberg M; Nord CE
J Chemother; 1996 Feb; 8(1):3-16. PubMed ID: 8835102
[TBL] [Abstract][Full Text] [Related]
27. Raman crystallographic studies of the intermediates formed by Ser130Gly SHV, a beta-lactamase that confers resistance to clinical inhibitors.
Helfand MS; Taracila MA; Totir MA; Bonomo RA; Buynak JD; van den Akker F; Carey PR
Biochemistry; 2007 Jul; 46(29):8689-99. PubMed ID: 17595114
[TBL] [Abstract][Full Text] [Related]
28. The complexed structure and antimicrobial activity of a non-beta-lactam inhibitor of AmpC beta-lactamase.
Powers RA; Blázquez J; Weston GS; Morosini MI; Baquero F; Shoichet BK
Protein Sci; 1999 Nov; 8(11):2330-7. PubMed ID: 10595535
[TBL] [Abstract][Full Text] [Related]
29. In-vitro evaluation of the four beta-lactamase inhibitors: BRL42715, clavulanic acid, sulbactam, and tazobactam.
Muratani T; Yokota E; Nakane T; Inoue E; Mitsuhashi S
J Antimicrob Chemother; 1993 Sep; 32(3):421-9. PubMed ID: 8262864
[TBL] [Abstract][Full Text] [Related]
30. β-lactam antibiotics: An overview from a medicinal chemistry perspective.
Lima LM; Silva BNMD; Barbosa G; Barreiro EJ
Eur J Med Chem; 2020 Dec; 208():112829. PubMed ID: 33002736
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of resistance to beta-lactam antibiotics.
Livermore DM
Scand J Infect Dis Suppl; 1991; 78():7-16. PubMed ID: 1947825
[TBL] [Abstract][Full Text] [Related]
32. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors.
Coleman K
Curr Opin Microbiol; 2011 Oct; 14(5):550-5. PubMed ID: 21840248
[TBL] [Abstract][Full Text] [Related]
33. Penicillin-Binding Proteins, β-Lactamases, and β-Lactamase Inhibitors in β-Lactam-Producing Actinobacteria: Self-Resistance Mechanisms.
Martin JF; Alvarez-Alvarez R; Liras P
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628478
[TBL] [Abstract][Full Text] [Related]
34. Recent developments in beta-lactamase research and their implications for the future.
Bush K
Rev Infect Dis; 1988; 10(4):681-90. PubMed ID: 3055169
[TBL] [Abstract][Full Text] [Related]
35. SHV-type beta-lactamases.
Tzouvelekis LS; Bonomo RA
Curr Pharm Des; 1999 Nov; 5(11):847-64. PubMed ID: 10539992
[TBL] [Abstract][Full Text] [Related]
36. Current challenges in antimicrobial chemotherapy: focus on ß-lactamase inhibition.
Bebrone C; Lassaux P; Vercheval L; Sohier JS; Jehaes A; Sauvage E; Galleni M
Drugs; 2010 Apr; 70(6):651-79. PubMed ID: 20394454
[TBL] [Abstract][Full Text] [Related]
37. Global dissemination of beta-lactamases mediating resistance to cephalosporins and carbapenems.
Gootz TD
Expert Rev Anti Infect Ther; 2004 Apr; 2(2):317-27. PubMed ID: 15482196
[TBL] [Abstract][Full Text] [Related]
38. Potentiation of beta-lactams against Pseudomonas aeruginosa strains by Ro 48-1256, a bridged monobactam inhibitor of AmpC beta-lactamases.
Livermore DM; Chen HY
J Antimicrob Chemother; 1997 Sep; 40(3):335-43. PubMed ID: 9338484
[TBL] [Abstract][Full Text] [Related]
39. The incidence of beta-lactamase-producing pathogens.
Acar JF; Kitzis MD; Gutmann L
APMIS Suppl; 1989; 5():2-8. PubMed ID: 2660867
[TBL] [Abstract][Full Text] [Related]
40. Interactions of tazobactam and clavulanate with inducibly- and constitutively-expressed Class I beta-lactamases.
Akova M; Yang Y; Livermore DM
J Antimicrob Chemother; 1990 Feb; 25(2):199-208. PubMed ID: 2158496
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
